Compare
HealthRX and Mochi Health
What each charges for compounded tirzepatide, as recorded on September 3, 2026. Mochi Health comes to $80 less in the first month. Terms and doses differ, so read both records before treating the figures as equivalent.
Side by side
$209
first month, everything required included
Injection, vial
◯ $209 advertised · 3-month plan
| Membership | None. “There are no separate visit fees or membership fees.” |
|---|---|
| Consultation fee | None. “There are no separate visit fees or membership fees.” |
| Pharmacy | Not yet checked |
| Terms published | 2 (3 mo, 12 mo) |
“Compounded Tirzepatide Once-weekly injection · Dual-incretin Dual-incretin therapy. Average 21% body-weight loss at 72 weeks in pivotal phase-3 trial. Compounded at a licensed 503A pharmacy. FROM $209 /mo (3-month plan) · as low as $179/mo on 12-month”
Read on healthrx.com, September 3, 2026 · Full record TR-0377
This is a paid link. If you enroll through it, Treatment Registry may earn a commission. It does not change what we record, and it does not change the price you pay.
$129
first month, everything required included
Form not recorded
◯ $90 advertised · Medication, starting dose
| Membership | Required, $79 per month |
|---|---|
| Consultation fee | Not disclosed on joinmochi.com as of August 31, 2026 |
| Pharmacy | Not disclosed on joinmochi.com as of August 31, 2026 |
| Terms published | 1 (1 mo) |
“New lower prices! Compounded Semaglutide starting at $99 $60 & Compounded Tirzepatide starting at $199 $90”
Read on joinmochi.com, September 2, 2026 · Full record TR-0007
We earn nothing from this link. Mochi Health has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
Notes
Neither company is recommended here. This page records two published prices with the dates they were read, and adds the charges each company states are required. What suits you depends on dose, terms, and clinical fit, none of which a price comparison can settle. See what this record is and is not.